Publication: Gal-GalNAc: a biomarker of colon carcinogenesis
Authors
Yang, G.Y. ; Shamsuddin, A.M.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The disaccharide tumor marker Gal-GalNAc
visualized by galactose oxidase-Schiff sequence is
commonly present in cancer cells and in rectal mucus of
patients with colon cancer. The expression of this marker
on tissue sections taken during experimental colon
carcinogenesis shows excellent correlation with human
precancerous lesions and cancers. A high proportions of
human precancerous lesions and even higher percentage
of colon cancers express this marker, whereas, no
expression is seen in the normal human large intestine.
Multifocal expression of the marker is seen throughout
the entire colon of patients with precancer and cancer;
these include dysplasia, dilated and distorted crypts,
regenerative dysplasia and hyperplastic crypts, as well as
the morphologically normal crypts remote from cancer.
Nearly identical pattern of Gal-GalNAc expression
throughout the entire colon also appear during rat colon
carcinogenesis induced by azoxzymethane including
non-expression by the normal and regenerative epithelia
during wound healing following mechanical injury.
Thus, Gal-GalNAc detected by the simple technique of
galactose oxidase-Schiff sequence, is a biomarker that
appears during the very early stages of progression of
carcinogenesis. The expression pattern supports the field
effect theory of carcinogenesis and also explains the
basis for mass screening for cancer and precancerous
conditions. Chemoprevention strategy using Gal-
GalNAc as an intermediate marker detected by accurate and cost-effective rectal mucus test may have great
potential.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.